1. Academic Validation
  2. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children

Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children

  • Helicobacter. 2007 Apr;12(2):132-5. doi: 10.1111/j.1523-5378.2007.00482.x.
Alexander A Nijevitch 1 Valery U Sataev Elsa N Akhmadeyeva Alexander G Arsamastsev
Affiliations

Affiliation

  • 1 Children's Republican Hospital, Ufa, Russia. aanj@rambler.ru
Abstract

Background: Proton Pump inhibitor-containing triple therapy with amoxicillin and metronidazole is recommended as initial treatment of Helicobacter pylori in childhood. However, eradication rate with this "classic" regimen is relatively low in Russia.

Aim: To evaluate empiric nifuratel, amoxicillin, and bismuth triple therapy for H. pylori gastritis in childhood.

Materials and methods: Pediatric outpatients with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8 mg/kg/day, q.d.s.), nifuratel (30 mg/kg/day, q.d.s.), and amoxicillin (50 mg/kg/day, q.d.s.) for 10 days. H. pylori status was determined before and after the treatment (in 4-6 weeks) by modified Giemsa staining.

Results: Seventy-three children (48 boys, 25 girls, age range 9-14) were entered. H. pylori was eradicated in 63 patients (86%; 95% confidence interval: 76.6-93.2; intention-to-treat and per protocol). There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and Others).

Conclusions: The combination of nifuratel, bismuth subcitrate, and amoxicillin was an effective and tolerable regimen for H. pylori eradication.

Figures
Products